Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 14, 2014 - Issue 1
Submit an article Journal homepage
149
Views
9
CrossRef citations to date
0
Altmetric
Reviews

Benefits of investment into modern medicines in Central–Eastern European countries

András InotaiSyreon Research Institute, Thököly út 119, Budapest 1146, HungaryCorrespondence[email protected]
,
Guenka PetrovaDepartment of Social Pharmacy and Pharmacoeconomics, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria
,
Dinko VitezicUniversity of Rijeka Medical School and University Hospital Centre Rijeka, Rijeka, Croatia
&
Zoltán KalóSyreon Research Institute, Thököly út 119, Budapest 1146, Hungary;Health Economics Research Centre, Eötvös Loránd Science University, Pázmány P. 1a, Budapest 1117, Hungary
Pages 71-79 | Published online: 19 Dec 2013

References

  • Okunade AA, Suraratdecha C. The pervasiveness of pharmaceutical expenditure inertia in the OECD countries. Soc. Sci. Med. 63, 225–238 (2006).
  • Moreno-Torres I, Puig-Junoy J, Raya JM. The impact of repeated cost containment policies on pharmaceutical expenditure: experience in Spain. Eur. J. Health Econ. 12, 563–573 (2011).
  • Lichtenberg FR. Benefits and costs of newer drugs: an update. Manage. Decis. Econ. 28(4-5), 485–490 (2007).
  • Kleinke JD. The price of progress: prescription drugs in the health care market. Health Aff. (Millwood). 20(5), 43–60 (2001).
  • Mark TL, Coffey RM. What drove private health insurance spending on mental health and substance abuse care, 1992–1999? Health Aff. (Millwood). 22(1), 165–172 (2003).
  • Organisation For Economic Co-Operation And Development (OECD). Key characteristics of the pharmaceutical sector in OECD economies. In: Health Policy Studies - Pharmaceutical Pricing Policies in a Global Market. OECD Publishing, Paris, France 23–50 (2008).
  • Baker D, Fugh-Bergman A. Do new drugs increase life expectancy? A Critique of a Manhattan Institute Paper. J. Gen. Intern. Med. 24(5), 678–682 (2009).
  • Organisation For Economic Co-Operation And Development (OECD). Health status. In: Health at a Glance 2012. OECD Publishing, Paris, France 15–48 (2012).
  • Kaló Z, Boncz I, Inotai A. Implications of economic crisis on health care decision-making in Hungary: An opportunity to change? J. Health Policy Outcomes Res. 1, 20–26 (2012).
  • van Baal PH, Polder JJ, de Wit GA et al. Lifetime medical costs of obesity: prevention no cure for increasing health expenditure. PLoS Med. 5(2), e29 (2008).
  • Barendregt JJ, Bonneux L, van der Maas PJ. The health care costs of smoking. N. Engl. J. Med. 337(15), 1052–1057 (1997).
  • Hanney S, Packwood T, Buxton M. Evaluating the benefits from health research and development centres categorization, a model and examples of application. Evaluation 6(2), 137–160 (2000).
  • Bloom DE, Canning D, Hu L, Liu Y, Mahal A, Yip W. The contribution of population health and demographic change to economic growth in China and India. J. Comp. Econ. 38(1), 17–33. (2010)
  • Drummond MF, O’Brien BJ, Stoddart LG, Torrance GW. Cost-Utility Analysis. Methods for Economic Evaluation of Health Care Programs (2nd Edition). Oxford University Press, NY, USA (1997).
  • Graber AM, Sculpher MJ. Cost effectiveness and payment policy. In: Handbook of Health Economics. Pauly MV, McGuire TG, Barros PP ( Eds). Elsevier, North Holland, Netherlands 471–498 (2011).
  • Kaló Z, Bodrogi J, Boncz I et al. Capacity building for HTA implementation in middle income countries: the case of Hungary. Value Health Regional Issues. (2013) ( In Press).
  • Stockholm Network Research Team. What price for a year of life? - The theory. In: A Healthy Market? What Price for a Year of Life? The Threshold Discussion in Health Technology Assessment. Stockholm Network, UK, 18–20 (2008).
  • Dolan PA, Olsen JA. Equity in health: the importance of different health streams. J. Health Econ. 20(5), 823–834 (2001).
  • Davies JE, Neidle S, Taylor DG. Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care? Br. J. Cancer. 106(1), 14–17 (2012).
  • Sharma A, Jacob A, Tandon M, Kumar D. Orphan drug: development trends and strategies. J. Pharm. Bioallied Sci. 2(4), 290–299 (2010).
  • Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet. J. Rare Dis. 6, 42 (2011).
  • Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: Do they deserve special status for funding? QJM 98(11), 829–836 (2005).
  • Stoimenova A, Manova M, Savova A, Angelovska B, Petrova G. Reimbursed orphan medicines in Bulgaria and the share of biotechnology-derived products. Biotechnol. Biotech. Eq. 2(25), 2418–2423 (2011).
  • Pavlović N, Stanimirov B, Stojančević M et al. An insight on differences in availability and reimbursement of orphan medicines among Serbia, Bulgaria and Sweden. Biotechnol. Biotech. Eq. 5(26), 3236–3241 (2012).
  • Piga A, Galanello R, Forni GL et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 91(7), 873–880 (2006).
  • Leontiadis GI, Sreedharan A, Dorward S et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol. Assess. 11(51), 1–164 (2007).
  • Gundert-Remy U, Dimovski A, Gajović S. Personalized medicine – where do we stand? Pouring some water into wine: a realistic perspective. Croat. Med. J. 53(4), 314–320 (2012).
  • Freire AC, Basit AW, Choudhary R, Piong CW, Merchant HA. Does sex matter? The influence of gender on gastrointestinal physiology and drug delivery. Int. J. Pharm. 415(1-2), 15–28 (2011).
  • Olivier C, Williams-Jones B, Godard B, Mikalson B, Ozdemir V. Personalized medicine, bioethics and social responsibilities: re-thinking the pharmaceutical industry to remedy inequities in patient care and international health. Curr. Pharmacogenomics Person. Med. 6(2), 108–120 (2008).
  • Hartmann B, Czock D, Keller F. Drug therapy in patients with chronic renal failure. Dtsch. Arztebl. Int. 107(37), 647–655 (2010).
  • Bock O, Felsenberg D. Bisphosphonates in the management of postmenopausal osteoporosis-optimizing efficacy in clinical practice. Clin. Interv. Aging 3(2), 279–297 (2008).
  • Bejarano V, Quinn M, Conaghan PG et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum. 59(10), 1467–1474 (2008).
  • Olsen KR, Hansen C, Abrahamsen B. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs-an analysis using national health databases. Osteoporos Int. 24(10), 2639–2647 (2013).
  • Centers for Disease Control and Prevention (CDC). Receipt of outpatient cardiac rehabilitation among heart attack survivors. MMWR Morb. Mortal. Wkly Rep. 57(4), 89–94 (2008).
  • Hashimoto M, Yatabe Y, Kaneda K, Honda K, Ikeda M. Impact of donepezil hydrochloride on the care burden of family caregivers of patients with Alzheimer’s disease. Psychogeriatrics 9(4), 196–203 (2009).
  • Craft AW. Childhood cancer-mainly curable so where next? Acta Paediatr. 89(4), 386–392 (2000).
  • Rafii MS, Aisen PS. Recent developments in Alzheimer’s disease therapeutics. BMC Med. 7, 7 (2009).
  • Danzon PM, Furukawa MF. Prices and availability of pharmaceuticals: evidence from nine countries. Health Aff. (Millwood) Suppl. Web Exclusives: W3, 521–536 (2003).
  • Kickbusch I, Gleicher D. Governance for health in the 21st century, World Health Organization. WHO Regional Office for Europe, Copenhagen, Denmark (2012).
  • Cholesterol Treatment Trialists’ (CTT); Mihaylova B, Emberson J et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380(9841), 581–590 (2012).
  • Kantarjian H, O’Brien S, Jabbour E et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 119, 1981–1987 (2012).
  • Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol. 23(19), 4265–4274 (2005).
  • Mitry E, Bouvier AM, Esteve J, Faivre J. Improvement in colorectal cancer survival: a population-based study. Eur. J. Cancer 41(15), 2297–2303 (2005).
  • Pulte D, Gondos A, Brenner H. Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990–2004. J. Natl Cancer Inst. 100(18): 1301–1309 (2008).
  • Viscomi S, Pastore G, Mosso ML et al. Population-based survival after childhood cancer diagnosed during 1970-98: a report from the Childhood Cancer Registry of Piedmont, Italy. Haematologica 88(9), 974–982 (2003).
  • Lee JG, Lee CY, Bae MK, Byun CS, Kim DJ, Chung KY. Changes in the demographics and prognoses of patients with resected non-small cell lung cancer: a 20-year experience at a single institution in Korea. J. Korean Med. Sci. 27(12), 1486–1490 (2012).
  • Law S, Kwong DL, Kwok KF et al. Improvement in treatment results and long-term survival of patients with esophageal cancer: impact of chemoradiation and change in treatment strategy. Ann. Surg. 238(3), 339–347 (2003).
  • Chakkera HA, Chertow GM, O’Hare AM, Amend WJ Jr, Gonwa TA. Regional variation in kidney transplant outcomes: trends over time. Clin. J. Am. Soc. Nephrol. 4(1), 152–159 (2009).
  • Briffa T, Hickling S, Knuiman M et al. Long term survival after evidence based treatment of acute myocardial infarction and revascularisation: follow-up of population based Perth MONICA cohort, 1984–2005. BMJ 26(338), b36 (2009).
  • Hallström B, Jönsson AC, Nerbrand C, Norrving B, Lindgren A. Stroke incidence and survival in the beginning of the 21st century in southern Sweden: comparisons with the late 20th century and projections into the future. Stroke 39(1), 10–15 (2008).
  • Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366(6), 520–529 (2012).
  • Moreland LW. Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis. Pharmacoeconomics 22(2 Suppl. 1), 39–53 (2004).
  • Prince FH, Geerdink LM, Borsboom GJ et al. Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis. Ann. Rheum. Dis. 69(1), 138–1342 (2010).
  • Yeomans ND, Tulassay Z, Juhász L et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid suppression trial: ranitidine versus omeprazole for NSAID-associated ulcer treatment (ASTRONAUT) Study Group. N. Engl. J. Med. 338(11), 719–726 (1998).
  • Braun J, McHugh N, Singh A, Wajdula JS, Sato R. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology 46, 999–1004 (2007).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.